Blueprint Medicines Corp Stock
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -0.570% | -2.235% | -2.778% | 92.308% | 5.422% | 161.194% | 34.564% |
| United Therapeutics | -1.530% | -0.429% | 5.568% | 95.860% | 14.042% | 128.137% | 184.971% |
| Ionis Pharmaceuticals Inc. | -1.960% | -1.110% | -1.566% | 169.073% | -5.650% | 98.698% | 80.264% |
News
Irresistible Change: How to Spot Real Growth
Phil Gilbert, serial entrepreneur and former general manager at IBM, joins this episode of Motley Fool Money to talk about his new book, Irresistible Change: A Blueprint for Earning Buy-In and
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This


